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Soluble Peptide Treatment Reverses CD8
T-Cell-Induced Disease in a Mouse Model of
Spontaneous Tissue-Selective Autoimmunity
So Yeon Paek1,2, Fumi Miyagawa1, Hong Zhang1, Jay T. Linton1, Shelley B. Hoover3, R. Mark Simpson3 and
Stephen I. Katz1
Transgenic (Tg) mouse models of autoimmunity have been used to express model antigens that can be
recognized by T cells or by autoantibodies. To identify mechanisms of CD8-mediated tissue-specific
autoimmune reactions and to identify potential treatments, we generated a double-transgenic (DTg) murine
model of autoimmunity by crossing keratin-14 (K14)-soluble chicken ovalbumin (sOVA) mice, which express
sOVA predominantly in external ear skin, with OT-I mice whose CD8 T cells express Va2/Vb5 regions of the TCR
and are specific for SIINFEKL peptide (chicken ovalbumin (OVA) peptide 257–264) in association with class I
major histocompatibility complex. The K14-sOVA/OT-I DTg mice develop a destructive process selectively
targeting the external ear pinnae in the first 6 days of life. The ear bud area develops an intense inflammatory
infiltrate of OT-I cells. Administration of the SIINFEKL peptide intravenously to pregnant F1 (filial 1, first filial
generation of animal offspring from cross-mating two parental types) mice and subsequently intraperitoneally
to newborn pups resulted in normal external ear development. Treatment with this self-peptide markedly
reduced OT-I cell numbers, as well as downregulated the CD8 co-receptor. This model can be useful in studying
localized, tissue-specific, immune-mediated skin disease, and provide information about potential therapies for
autoimmune diseases in which specific molecular targets are known.
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INTRODUCTION
Autoimmunity results when the immune system fails to
control autoregulatory processes and cannot differentiate self
from foreign antigens. Autoimmune diseases may be T-cell-
or B-cell-mediated and may target self-antigens or produce
autoantibodies targeting specific tissues. Identifying molecu-
lar target antigens has been a major investigative challenge
in many autoimmune disorders, and for those diseases
with known antigens, such as pemphigus vulgaris or bullous
pemphigoid (Goldberg et al., 1984), the difficulty remains in
the development of antigen-specific therapies (Caspi, 2008).
Autoreactive CD8 T cells have a critical pathogenic role in
organ-specific autoimmune diseases (Liblau et al., 2002; Lohr
et al., 2005). Their mechanism of action has been studied in
various diseases affecting the skin, including alopecia areata,
psoriasis vulgaris, vitiligo, and cutaneous lupus erythematosus
(Walter and Santamaria, 2005). To study the mechanisms of
autoreactive CD8 T cells against skin, we previously estab-
lished three strains of keratin-14 (K14)-soluble chicken
ovalbumin (sOVA) mice that express different levels of
ovalbumin (OVA): K14-sOVA #5, #15, and #17 (Miyagawa
et al., 2010). K14-sOVA (#15) mice express the highest levels of
OVA mRNA in multiple organs, whereas #5 and #17 mice
express much lower levels of OVA mRNA than #15 mice.
When K14-sOVA (#15) mice were mated with OT-I mice, 83%
of the K14-sOVA/OT-I F1 (filial 1, first filial generation of animal
offspring from cross-mating two parental types) pups died
because of multiorgan inflammation (Gutermuth et al., 2009).
We then hypothesized that we could generate a localized
skin disease model by crossing K14-sOVA transgenic (Tg) mice
expressing lower levels of OVA with OT-I mice. In the current
study, we evaluate the K14-sOVA/OT-I (#5) and K14-sOVA/
OT-I (#17) double-transgenic (DTg) mice and investigate the
role of antigen-specific therapy in modifying the disease in
these mice. Except for the finding that the #17 model
demonstrated slightly higher levels of OVA mRNA, the K14-
sOVA/OT-I (#5 and #17) strains can be considered identical.
Both (#5 and #17) DTg mice demonstrate selective tissue
destruction of the external pinnae because of inflammatory
infiltration of CD8þ T cells during the first few days of life.
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Previous attempts have been made to (1) study how
defective TCR surface expression or signaling correlate with
CD8þ T-cell tolerance (Dubois et al., 1998) and to (2) use
self-peptides in the induction of antigen-specific tolerance
(Brocke et al., 1996; Aichele et al., 1997; Liblau et al., 1997).
Using a diabetic mouse model, Bercovici et al. (2000) found
that administration of an agonist peptide in the early neonatal
period disrupted the progression of autoimmune diabetes due
to downregulation of autoreactive CD8þ T cells through
apoptosis-induced cell death. Injection of soluble hemagglu-
tinin peptide into DTg autoimmune diabetic mice on days
3–5 after birth resulted in prolonged survival of the mice via a
CD8-mediated process.
We previously reported that administration of sOVA
peptide resulted in a dose-dependent increase in the survival
of the K14-sOVA/OT-I (#15) DTg mice (Gutermuth et al.,
2009). The aim of the current study was to elucidate the
mechanism(s) of selective tissue destruction and to attempt to
prevent that inflammation and subsequent loss of pinnae.
Administration of self-peptide into K14-sOVA (#5 and
#17) DTg mice at critical time points in the prenatal and
neonatal period eliminated the inflammation-producing OT-I
cells and induced CD8 co-receptor downregulation, allowing
for normal development of ears in the DTg mice.
RESULTS
K14-sOVA/OT-I (#5 and #17) F1 DTg pups develop normally,
except for the bilateral loss of the pinnae
The K14-sOVA (#5 and #17) strains were generated similarly
to the Tg mice described in Shibaki et al. (2004), but without
the platelet-derived growth factor-receptor transmembrane
domain. When these mice were crossed with OT-I mice, the
progeny developed normally but underwent a destructive
process selectively targeting the outer ear (Figure 1). At day 2,
there was hyperemia of dermal vasculature, followed by
epidermal necrosis and intraepidermal pustule formation on
day 3. This progressed to involve both cranial and lateral
pinnal epidermis, and the underlying facial epidermis, over
the following 2–3 days. By day 6 or 7, an inflammatory cleft
had formed between the lateral surface of the pinna and
adjacent facial skin that adhered distally on days 7–8 and
closed by dermal adhesion on day 9. The cranial epidermal
surfaces of pinnae regenerated on days 7–9, whereas the
accompanying inflammatory dermal infiltrate resulted in
dysplastic chondroplasia of auricular cartilage precursors
and permanent disfigurement of the external ear. Histology of
tongue, esophagus, and trunk skin of K14-sOVA/OT-I (#5 and
#17) mice on days 4, 8, and 14 after birth was normal,
indicating that the inflammatory process was limited to the
ears (Supplementary Figure S1 online).
Ear skin of K14-sOVA (#5 and #17) mice expressed high levels
of OVA mRNA
To determine why the inflammation was limited to the ears in
our mouse model, the OVA mRNA expression in different
tissues of K14-sOVA single Tg mice were assessed. Cell
suspensions were prepared from ear skin, back skin, thymus,
tongue, esophagus, and liver of wild-type C57BL/6 and
K14-sOVA (#5 and #17) single Tg mice. OVA transgene
mRNA expression levels were quantified by real-time PCR
with mGAPDH as the housekeeping gene (Figure 2). Ear skin
exhibited higher levels of OVA mRNA expression compared
with other tissues examined. Thus, the presence of immune
cell-mediated inflammation and the resulting earless pheno-
type in the sOVA/OT-I (#5 and #17) mice corresponded with
the level of mRNA OVA expression in the single Tg mice.
Inflammatory infiltrates in K14-sOVA/OT-I DTg ear buds
comprised CD8þ T cells and were present before birth
To determine whether inflammation in the ear was caused by
endogenous OT-I cells, cryosections taken from ear buds of
DTg pups on days 1, 2, and 3 after birth were stained for CD8
(Figure 3a). Immunofluorescence microscopy exhibited a
collection of CD8-positive cells in the dermis, closely
abutting the epidermis, on all 3 days. FACS analysis of cell
suspensions from ear buds of day 5 K14-sOVA/OT-I DTg
pups demonstrated that these CD8-positive cells were also
Va2/Vb5 positive (10.8%) when gated on the total lympho-
cyte population, indicating again that the OT-I cells infiltrated
the ear buds (Figure 3b). Immunostaining for CD4þ T cells
was negative (data not shown).
As inflammatory infiltrates were present in ear buds as
early as day 1, we further evaluated K14-sOVA/OT-I (#5 and
#17) mice on days E18 (embryonic day 18) and E19,
immediately before birth, to determine whether the process
occurred in utero. External ear taken during embryonic
development day 19 (E19) revealed morphological evidence
of a zone of coordinate, epidermal keratinocyte programmed
cell death (Figure 3c, middle and right arrows) that eventually
led to the opening of the external auditory canal (Figure 3c,
open space at left arrow) and the ultimate creation of lateral
pinnal and facial skin surfaces. These surfaces re-epithelial-
ized, freeing the pinna as an appendage from the rest of the
head. The epidermal structure was in the same topographical
region of epidermolysis manifest at 3 days in K14-sOVA/OT-I
mice. Older mice expressed resolved re-epithelialized skin
over misshapen chondrified cartilage and dilated external
auditory canals (not shown). FACS analysis of spleens of K14-
sOVA/OT-I (#5 and #17) pups at day E18 demonstrated that
cells were positive for Va2 and Vb5 (11.4 to 24.7%), among
which cells were also positive for CD8 (Figure 3d). These
Va2/Vb5þCD8þ (OT-I) cells are likely responsible for the
eventual tissue destruction.
Administration of CD8-depleting antibody in utero resulted in
normal ear development
To definitively prove that the CD8þOT-I cells caused the
destruction of the pinna and that the destructive process in
K14-sOVA/OT-I (#5 and #17) DTg mice began before birth,
three doses of the CD8-depleting antibody (clone YTS169.4)
were administered intraperitoneally (i.p.) to pregnant
K14-sOVA (#5 and #17) dams on days E14, E16, and E18
of gestation. All pups subsequently born to these treated
mothers exhibited normal ear development and lacked
the inflammatory infiltrates that were present in untreated
K14-sOVA/OT-I pups (Figure 3e, compare with Figure 1).
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This result indicates that CD8þ T cells are responsible for
tissue destruction of the ear.
SIINFEKL peptide treatment rescued the ear phenotype in
K14-sOVA/OT-I (#5 and #17) mice
Treatment of K14-sOVA (#5 and #17) mothers with CD8-
depleting antibody was effective in preventing the destructive
process. However, it is a nonspecific treatment and affects all
CD8 T cells. Thus, we determined whether similar results
could be obtained using the TCR-recognized SIINFEKL
peptide (chicken ovalbumin peptide 257–264) to target
OT-I cells specifically and leave the remainder of the immune
system intact. Initial i.p. injections of pregnant K14-sOVA
(#5 and #17) mice with 100 mg of peptide had no effect on ear
inflammation and destruction, but repeated larger doses
(300 mg to 1mg) resulted in some pups being born with partial
Day 1 Day 2 Day 3 Day 4 Day 5
Day 6 Day 7 Day 8 Day 9 C57BL/6 day 9
b
a
Figure 1. Development of keratin-14-soluble chicken ovalbumin/OT-I (#17) double-transgenic (DTg) mouse ear on days 1–9 after birth. Hematoxylin and
eosin stain (a) DTg mice developed normally until birth, after which the pinnae (external ear auricles) developed bullae at the dermal–epidermal junction
associated with progressive epidermal necrosis and leukocyte infiltration over days 3–6, resulting in the loss of epidermis on the pinnal surface, and eventually
the loss of external ears by day 10. The crown of the mouse is on the right and the ventral aspect on the left (bars¼ 100 mm). (b) DTg mice ears displayed at higher
resolution from mouse #17 at day 3 (d3; left and middle panels), and mouse #5 at d4 (right panel). The changes include evolving bullae at the dermal–epidermal
junction associated with epidermal necrosis and leukocyte infiltration (bars¼25 mm).
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or full ears (Table 1). As i.p.-injected peptide may have a
variable distribution, we administered intravenous (i.v.)
injections of 200mg peptide to pregnant dams on days E14,
E16, and E18, and obtained a larger percentage of pups
with intact ears (Table 1). The inconsistency of phenotype
reversal appeared to be due to the persistence of selective ear
tissue destruction after birth. Therefore, in addition to the i.v.
dosing of the pregnant dams, we continued to administer
SIINFEKL peptide to the newborn pups at 50 mg i.p. after birth.
All pups (100%) whose pregnant mothers received SIINFEKL
peptide i.v. in utero and who then received peptide i.p. after
birth developed normal-looking ears (Table 1). Complete
prevention of ear tissue destruction in K14-sOVA/OT-I (#5
and #17) mice was obtained with the optimal injection
schedule shown in Supplementary Figure S2 online: i.v.
200mg SIINFEKL peptide on days E14, E16, and E18,
followed by i.p. 50 mg peptide on days 2 and 4 after birth.
These peptide-treated mice did not experience ear loss as
adults, indicating that peptide treatment at a critical time
period permanently reversed ear destruction (data not
shown). Mice treated with control influenza NP peptide
(ILRGSVAHK) in the same concentration and same dosing
regimen did not develop ears. By immunofluorescence
microscopy, many fewer CD8þ T cells infiltrated the dermis
(Figure 3a).
Peptide treatment markedly reduced OT-I cell numbers at early
time points
To determine the mechanism of phenotype reversal in our
mouse model of tissue-specific autoimmunity, we analyzed
the effect of peptide treatment on the spleen. Spleens from
K14-sOVA/OT-I (#5) untreated and K14-sOVA/OT-I (#5 and
#17) pups treated with the optimal peptide dosing schedule
were harvested on days E18, 3, 5, and 9 after birth, pooled
into single-cell suspensions, and stained with anti-Va2 and
Vb5. Mice evaluated at days 5 and 9 continued to receive i.p.
50 mg of peptide on days 4 and 6.
A decrease in the number of Va2/Vb5-positive OT-I cells
in spleens of peptide-treated K14-sOVA/OT-I (#5) mice
compared with untreated mice on day E18 and day 3 after
birth was observed, indicating that peptide injection mark-
edly decreased OT-I cell numbers in the spleen. Interestingly,
the percentage of OT-I cells in peptide-treated mice
increased on days 5 and 9, whereas it decreased in untreated
K14-sOVA/OT-I (#5) mice (Figure 4a). These changes were
not associated with differences in the total number of
splenocytes (data not shown). The increase in OT-I cells at
days 5 and 9 may be due to the expansion of peripheral
CD8þ T cells following peptide injection, as observed in the
studies of Bercovici et al. (2000). However, this proliferation
does not result in immune inflammatory changes or ear
destruction.
Peptide treatment induced downregulation of the CD8
co-receptor
As the number of OT-I cells increased at later time points
after peptide injection (Figure 4a), elimination of OT-I cells
may not be the only mechanism by which the injected
peptides function. We next determined whether the CD8
expression levels of OT-I cells were changed by peptide
injection. Spleens of untreated K14-sOVA/OT-I (#5) and
peptide-treated K14-sOVA/OT-I (#5 and #17) mice were
harvested on days 3, 5, and 9, and stained for CD8. The mean
fluorescence intensity of CD8 at all time points in OT-I cells
of peptide-treated DTg mice was lower than that in untreated
mice, suggesting that CD8 was downregulated upon peptide
injection, and this downregulation persisted (Figure 4b).
These data suggest that CD8 co-receptor downregulation may
also be a factor in the peptide-induced prevention of pinna
destruction.
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Figure 2. OVA mRNA expression levels in different tissues from C57BL/6 and K14-sOVA (#5 and #17) adult single Tg mice. The OVA Tg mRNA
expression levels were quantified by real-time PCR with mGAPDH as the housekeeping gene. The average of two mice from each group is shown.
K14-sOVA, keratin-14-soluble chicken ovalbumin; OVA, ovalbumin; Tg, transgene.
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K14-sOVA/OT-I (#5 and #17) mice treated with SIINFEKL
peptide demonstrated an activated CD8 T-cell phenotype at an
earlier time point than untreated mice
To further determine the mechanism of peptide treatment
efficacy, OT-I cell activation status in vivo was evaluated by
FACS staining of splenocytes for surface activation markers
after gating on the OT-I population of cells. OT-I cells from
peptide-treated K14-sOVA/OT-I (#5 and #17) mice exhibited
a CD25high CD44high CD62Llow CD69high activated pheno-
type on postnatal day 3, whereas untreated mice exhibited a
a
b
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Figure 3. Inflammatory infiltrates in K14-sOVA/OT-I (#5 and #17) mice ears. (a) Few T cells in the dermis of OVA-peptide-treated DTg mice, compared
with more florid dermal infiltration of CD8þ T cells (red; 4,6-diamidino-2-phenylindole blue) observed in d1–3 DTg control mice (epidermis on right;
original magnification  40). (b) FACS of cell suspensions (liberase-digested) from day 5 DTg pup ears, and (c) histology of DTg mice at embryonic day 19
(day E19). Arrows represent the zone of epidermal–keratinocyte programmed cell death; open space at left arrow is precursor to external auditory canal
(bars¼ 50 mm). (d) FACS data of spleens of day E18 DTg mice with Va2/Vb5-positive TCR (range 11.4–24.7%) and CD8þ T cells (range 10.8–23.9%).
(e) Histology of ears of CD-8-depleted DTg mice is normal (bars¼ 100mm). APC, allophycocyanin; DTg, double transgenic; K14-sOVA, keratin-14-soluble
chicken ovalbumin; OVA, ovalbumin; PE, phycoerythrin.
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CD25low CD44low CD62Lhigh CD69low naive phenotype on
day 3 (Figure 5). In peptide-treated mice, OT-I cells rapidly
became memory-like cells, downregulating CD25 and CD69
and upregulating CD44 and CD62L by postnatal day 5. This
suggests that peptide injection activated OT-I cells. In
contrast, untreated K14-sOVA/OT-I mice (#5) demonstrated
an activated effector CD8 T-cell expression pattern on day 9,
with downregulation of CD62L and moderate upregulation of
CD25, CD44, and CD69.
The results indicate that early after exposure to peptide,
the OT-I cells in these newborn DTg mice are not activated, a
finding that correlates with the continuing normal pinnal
development described above in treated mice. The late (at
P9) activation of OT-I cells in these DTg mice is puzzling, but
may signify that their cytotoxic potential is decreased in fully
formed ears. The timing of the reduction of OVA-reactive
OT-I cells in peptide-treated DTg mice (Figure 4a) is well
correlated with upregulation of activation markers on OT-I
cells at approximately 3 days of age (Figure 5), suggesting that
peptide injection eliminates OT-I cells through activation-
induced cell death.
DISCUSSION
In this study, the development and evaluation of a localized
skin disease model of CD8þ T-cell–mediated autoimmunity
and the potential for antigen-specific therapy are presented.
Destruction of ears of K14-sOVA/OT-I (#5 and #17) DTg pups
in response to OVA self-antigen mimicry in external ear skin
was obviated by self-peptide treatment, which markedly
reduced Va2/Vb5þCD8þ OT-I cells that participate in tissue
destruction, likely by activation-induced cell death, and
downregulated the CD8 co-receptor in the postnatal period.
Although we initially thought that Va2Vb5 CD8þ T cells
in our DTg mouse model might be tolerized in utero, we
found that spontaneous autoimmunity ensued in these mice.
There are examples in the literature that support the findings
described herein (Verdaguer et al., 1997; Bercovici et al.,
2000). DTg systems are preferred models to study peripheral
immune tolerance of activated CD8þ T cells that have
escaped thymic deletion and are involved in ongoing disease
processes. Mechanisms of peripheral tolerance include
clonal anergy, reduced surface expression of TCRs and
CD8 T-cell deletion, immune deviation, and TCR editing
(McGargill et al., 2000; Park et al., 2007). In clonal anergy,
after encountering an antigen, T cells rapidly enter the cell
cycle, express early activation markers, and enter a state of
hypo-responsiveness with decreased proliferation. CD8-
specific T cells can further undergo peripheral clonal deletion
after antigen administration, resulting in either complete or
partial loss of memory T cells. Autoreactive T cells have been
stimulated to undergo deletion mediated by apoptosis when
peptide treatment is used in animal models of experimental
autoimmune neuritis and encephalomyelitis (Weishaupt
et al., 1997; Ishigami et al., 1998). Finally, a shift from Th1
to Th2 response may occur in some tolerance models
because of mechanisms of immune deviation (McGargill
et al., 2002).
In our peptide-treated DTg mice, a decrease in the
percentage of Va2/Vb5þ CD8 T cells and downregulation
of the CD8 co-receptor appear to be mechanisms by which
soluble peptide therapy exerts its protective effects. Targeted
therapy using soluble peptides against T-cell populations has
become a topic of interest in immunology (Larche and
Wraith, 2005). This Tg mouse model is informative with
regard to peripheral tolerance mechanisms and may be used
to study localized CD8-mediated skin diseases where there is
intense superficial dermal infiltration by T cells, such as in
lichen planus and fixed drug eruptions. The pathogenesis of
both these conditions is unclear, but studies have demon-
strated involvement of intraepidermal CD8 T cells (Gilhar
et al., 1989; Shiohara, 2009; Duarte et al., 2010; Roopashree
et al., 2010). Our model may also provide insight into
potential therapeutic vaccines for children at high risk for
development of tissue-selective autoimmune diseases, parti-
cularly diabetes.
MATERIALS AND METHODS
Mice
All mice used in this study were maintained on a 12-h light–dark
cycle with free access to food and water in a clean animal facility
(free from mouse hepatitis virus and pinworm). Animals were
handled, bred, and used in accordance with institutional policies
and with prior approval by the Animal Care and Use Committee of
the National Institutes of Health. K14-sOVA Tg mice were generated
in a manner similar to the membrane-bound K14-membrane-bound
chicken ovalbumin mice previously described (Shibaki et al., 2004),
Table 1. SIINFEKL peptide treatment of K14-sOVA/OT-I (#5 and #17) mice
Method Total pups Full/partial ears No ears
i.p. in utero (100mg–1mg) 62 14 (23%) 48 (77%)
i.v. in utero (200mg) 36 14 (39%) 22 (61%)
i.v. in utero (200mg)þ i.p. after birth (50 mg) 39 39 (100%) 0 (0%)
i.v. in utero (200mg)þ i.p. after birth (50 mg)1 8 0 (0%) 8 (100%)
i.p. after birth (50 mg) 30 16 (53%) 14 (47%)
Abbreviations: i.p., intraperitoneal; i.v., intravenous; K14-sOVA, keratin-14-soluble chicken ovalbumin.
Double-transgenic pups treated with self-peptide only in utero inconsistently developed ears, whereas pups whose mothers were treated both i.v. or i.p. and
were then treated i.p. after birth with ovalbumin peptide developed normal-looking ears 100% of the time.
1These mice were treated identically to the group above except that a control NP influenza peptide was used instead of the SIINFEKL peptide.
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Figure 4. Marked reduction of OT-I cell numbers at earlier time points and downregulation of the CD8 co-receptor following peptide treatment. (a) FACS
analysis of spleens of untreated and peptide-treated K14-sOVA/OT-I (#5 and #17) pups harvested on days E18, 3, 5, and 9 and stained for Va2/Vb5
(OT-I cells). (b) Spleens harvested and pooled from untreated K14-sOVA/OT-I (#5) and peptide-treated K14-sOVA/OT-I (#5 and #17) mice on days 3, 5,
and 9 were stained for CD8. Mean fluorescence intensity of CD8 in OT-I cells was lower at all time points in peptide-treated mice compared with
untreated mice. K14-sOVA, keratin-14-soluble chicken ovalbumin; PE, phycoerythrin.
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but without the platelet-derived growth factor-receptor transmem-
brane domain, myc, and hemagglutinin sequences. The K14-sOVA
(#5) and K14-sOVA (#17) mice were crossed with OT-I mice
(OVA257264-specific, class-I restricted TCR Tg mice) to generate
sOVA/OT-I (#5 and #17) DTg mice. OT-I mice were obtained from
Dr J. Kapp (Emory University, Atlanta, GA).
Timed pregnancies
Pregnancies were timed by limiting the period of mating to 24 h
(classified as day E0–E1) between K14-sOVA (#5 or #17) female and
OT-I male mice. Mice were separated by gender after that period
and observed until the first sign of pregnancy, roughly on day E14.
Birth was considered day 0.
Day 3
100 101 102
FL4-H: CD25-APC FL4-H: CD25-APC FL4-H: CD25-APC
CD25-APC
103 104 100 101 102 103 104 100 101 102 103 104
100 101 102
FL4-H: CD44-APC FL4-H: CD44-APC FL4-H: CD44-APC
CD44-APC
103 104 100 101 102 103 104 100 101 102 103 104
100 101 102
FL4-H: CD62L-APC FL4-H: CD62L-APC FL4-H: CD62L-APC
CD62L-APC
103 104 100 101 102 103 104 100 101 102 103 104
100 101 102
FL4-H: CD69-APC FL4-H: CD69-APC FL4-H: CD69-APC
CD69-APC
103 104 100 101 102 103 104 100 101 102 103 104
Day 9Day 5
Figure 5. Activation markers on OT-I cells in vivo. OT-I cells of untreated and peptide-treated K14-sOVA/OT-I DTg pup spleens were stained for the surface
markers CD25, CD44, CD62L, and CD69 on days 3, 5, and 9 after birth. K14-sOVA/OT-I pups treated with SIINFEKL peptide demonstrated an activated
phenotype on postnatal day 3, but were CD25low CD44high CD62Lhigh CD69low by days 5 and 9. Legend: red, sOVA/OT-I (#5) untreated; blue, sOVA/OT-I
(#5) peptide treated; green, sOVA/OT-I (#17) peptide treated. APC, allophycocyanin; DTg, double transgenic; K14-sOVA, keratin-14-soluble chicken
ovalbumin.
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Quantitative real-time PCR
Total RNA was extracted from various tissues using the RNeasy Plus
Kit (QIAGEN, Clarita, CA) according to the manufacturer’s instruc-
tions. Quantitative real-time PCR mixtures were assembled using the
iScript One-Step RT-PCR Kit with SYBR Green, and quantitative real-
time PCR was performed in a Chromo4 RT-PCR machine (Bio-Rad,
Hercules, CA). The following primer pairs were used: mGAPDH,
forward primer 50-CGTGTTCCTACCCCCAATGT-30, reverse primer
50-TGTCATCATACTTGGCAGGTTTCT-30; OVA, forward primer 50-
GGCATCAATGGCTTCTGAGAA-30, reverse primer 50-CCAACATGC
TCATTGTCCCA-30.
CD8 T-cell depletion
A measure of 250mg of the anti-CD8 mAb YTS169.4. (1mgml1,
Serotec, Raleigh, NC) was injected i.p. into pregnant K14-sOVA (17)
mice on days E14, E16, and E18. The 250 mg dose was determined to
sufficiently deplete CD8 T cells.
Peptide treatment
SIINFEKL peptide (monomeric ovalbumin peptide, composition Ser-
Ile-Ile-Asn-Phe-Glu-Lys-Leu) was synthesized by PolyPeptide Group
(San Diego, CA) and certified as 99.3% pure by HPLC. Initial studies
involved i.p. injection of 100mg to 1mg SIINFEKL peptide in 1 PBS
(Life Technologies (GIBCO), Grand Island, NY) into pregnant mice.
In later studies, SIINFEKL peptide (1mgml1 in PBS) was injected
i.v. (200 mg) on days E14, E16, and E18 into pregnant K14-sOVA (#5)
and K14-sOVA (#17) mice. Pups of these litters were subsequently
injected i.p. (50 mg) on postnatal days 2 and 4. Control peptide was
used at the same concentrations as the latter for both i.v. and i.p.
injections with Influenza NP (266–274) from PolyPeptide Labora-
tories in Strasbourg, France. The sequence is as follows: Ile-Leu-Arg-
Gly-Ser-Val-Ala-His-Lys (ILRGSVAHK).
Immunofluorescence microscopy
Ear buds from sOVA/OT-I (#17) pups were harvested, frozen in Neg-
50 medium (Thermo Scientific, Life Technologies (GIBCO)), and
stored at 20 1C. Cryosections were cut at 6 mm thickness and
mounted onto silane-prep slides (Sigma, St Louis, MO). Before
staining, slides were maintained at room temperature for 30min to
defrost. For immunofluorescence staining, slides were blocked with
3% skim milk-PBSþ 5% goat serum, rinsed in PBS, and incubated
with any of the following primary antibodies (BD Pharmingen,
San Jose, CA): rat anti-mouse CD8a (2mgml1), isotype rat IgG2a
(2mgml1). After three PBS washes, secondary antibody (Alexa Fluor-
568 goat anti-rat IgG, Invitrogen, Carlsbad, CA) was added. The
slides were again washed in PBS three times before being mounted
with Prolong Gold with DAPI (Invitrogen). Images were viewed with
a fluorescence microscope (Zeiss MicroImaging, Thornwood, NY).
Flow cytometry
Single-cell suspensions were prepared from either pooled ear buds
or pooled spleens of sOVA/OT-I (#5 and #17) mice and resuspended
in RPMI with 5% fetal bovine serum. RBCs were lysed using
ACK lysing buffer (Invitrogen). Cell counts were obtained manually
with Trypan blue exclusion. For cell surface staining, FITC-
conjugated Va2 (B20.1.1), phycoerythrin-conjugated Vb5 (MR9.1),
and allophycocyanin-conjugated anti-CD8, CD25, CD44, CD62L,
CD69, and isotype control antibodies were used (BD Pharmingen).
Stained cells were evaluated on an FACSCalibur (BD Biosciences,
San Jose, CA) and analyzed using the Flo Jo software (Tree Star,
Ashland, OR).
Histopathology
The heads from embryonic and neonatal mice were fixed in 10%
neutral-buffered formalin. Paraffin-embedded tissues were sectioned
and stained with hematoxylin and eosin using standard techniques
(American HistoLabs, Gaithersburg, MD).
Clinical score
Ear development of sOVA/OT-I (#5 and #17) pups was assessed and
classified into the following categories by a blinded grader: no ears,
partial ears, and fully formed ears. This procedure was standardized
for all pups evaluated.
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